Aktis – Talk Bio

Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026

2 weeks ago talkbio0Tagged Aktis, AKTS, Biotech IPOs, bounce, Capital Markets, CD276 gene, Eli Lilly backing, IPO, NECTIN4 gene, Neoplasms, Radiopharmaceuticals, Window (physical object)

Aktis Oncology IPO; AKTS; 2026 biotech IPOs; IPO bounce; radiopharmaceuticals; Eli Lilly backing; biotech capital markets; Nectin-4; B7-H3; IPO window 2026

Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026

3 weeks ago talkbio0Tagged Aktis, IPO, methionine, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M

Aktis Oncology Files for IPO to Fund Lilly-Partnered Radiopharma Pipeline

1 month ago talkbio0Tagged Aktis, AKTS, AKY-1189, eli lilly, IPO, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; Eli Lilly; radiopharmaceuticals; AKY-1189; AKTS

Aktis Oncology Secures $175M Series B Funding with Backing from Industry Giants

1 year ago talkbio0Tagged Aktis, BMY, Cancer Therapeutic Procedure, CILK1 gene, Drug Industry, Eli Lilly, Investments, Neoplasms, Series B, targeted alpha radiopharmaceuticals

Aktis Oncology, Series B funding, targeted alpha radiopharmaceuticals, cancer treatment, pharmaceutical industry, investment, Lilly, BMY, MRK.

Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition

2 years ago talkbio0Tagged Acquisition (action), Aktis, Cancer Therapeutic Procedure, cellular targeting, Eli Lilly, portfolio, Radiopharmaceuticals

Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment